pSivida collaborates with Cirrus on drug development using BioSilicon
International nanotechnology company pSivida has signed a contract with US-based r&d company Cirrus Pharmaceuticals to accelerate and expand development of a number of specific drug candidates formulated in BioSilicon.
International nanotechnology company pSivida has signed a contract with US-based r&d company Cirrus Pharmaceuticals to accelerate and expand development of a number of specific drug candidates formulated in BioSilicon.
BioSilicon offers improved drug delivery by allowing drug molecules to be held in nano-sized pockets that release tiny pulses of drug as the BioSilicon dissolves.
This latest development contract will aim to generate new products based on reformulating existing generic and proprietary drugs utilising BioSilicon. If the reformulations demonstrate improved efficacy or safety compared with the original product, then pSivida will be able to claim patent protection on its new products.
All intellectual property developed through this collaboration relating to BioSilicon will be wholly owned by pSivida.
In a separate move, pSivida is currently in negotiations to acquire a US-based drug delivery company with the aim of creating a global drug delivery business specialising in nanotechnology. It hopes to announce details soon.